Boston Archives

Neoadjuvant Therapy for High-Risk Prostate Cancer

Posted by Adam S. Kibel, MD | Aug 2019

Adam S. Kibel, MD, argues that, while it is common to debate the best intervention method for local prostate cancer, there also must be an emphasis on the systemic treatment of micro-metastatic disease in the interest of decreasing disease-specific death. He then reviews the impact of timing, duration, and intensity of systemic therapy on patient outcomes, focusing on four trials evaluating neoadjuvant therapy for high-risk prostate cancer.

Management of Adverse Pathology after Radical Prostatectomy

Posted by Jason A. Efstathiou, MD, DPhil | Jun 2019

Jason A. Efstathiou, MD, DPhil, reviews the results of randomized studies and large retrospective experiences evaluating the efficacy, safety, and timing of post-prostatectomy radiation. He discusses the role of androgen deprivation therapy in addition to radiation in the salvage postoperative setting, and the potential use of genomic and advanced imaging biomarkers in patient treatment selection.

Testosterone Therapy in Men with Advanced Prostate Cancer

Posted by Abraham Morgentaler, MD, FACS | Jun 2019

Abraham Morgentaler, MD, explains new concepts that could subvert the long-held belief that high levels of testosterone exacerbate prostate cancer growth. He discusses the androgen saturation model, as well as the benefits of testosterone therapy for patients’ quality of life.

The Role of FSH in Prostate Cancer

Posted by Marc B. Garnick, MD | Mar 2018

Marc B. Garnick, MD, discusses whether or not follicle stimulating hormone (FSH) affects prostate cancer progression and cause adverse effects when used in combination with androgen deprivation therapy (ADT). He presents evidence for both the pro and con sides of this argument.

Testosterone and Prostate Cancer: Is There a Link?

Posted by Abraham Morgentaler, MD, FACS | Jul 2017

Dr. Abraham Morgentaler presented “Testosterone and Prostate Cancer: Is There a Link?”...